Interferon beta-1a

Synairgen PLC is conducting a phase II trial with SNG001, an inhaled antiviral, in 450 critically ill patients on mechanical ventilation due to respiratory viruses, aiming to reduce mortality rates (25%-45%). The trial is funded by Tetragon up to £18M, with an open offer accepting up to £6M. If Tetragon's ownership exceeds 75%, Synairgen may delist from AIM.

Synairgen PLC plans to raise up to £25 million to fund SNG001 development, an inhaled interferon beta treatment for respiratory viral infections. TFG Asset Management backs the initiative, acquiring shares at a 47% discount. The funds will support a phase II trial in mechanically ventilated patients, aiming to reduce mortality rates. The investment also positions SNG001 for potential partnerships. If fundraising fails to meet the £2.9 million minimum, Synairgen may delist from AIM.

Three university professors, Ratko Djukanovic, Stephen Holgate, and Donna Davies, became millionaires after their company, Synairgen, achieved a 3,000% share increase due to a successful COVID-19 drug trial. The drug, SNG001, administered via inhaler, showed significant recovery and reduced severe illness rates in patients.

Ozanimod treatment in relapsing MS patients showed sustained reductions in brain volume loss for up to 5 years in the DAYBREAK trial, with stable and low rates of whole brain volume through month 60. Switching from interferon-beta-1a to ozanimod reduced WBV loss rates, and cortical grey matter volume loss reversed after 12 months on ozanimod.